{"url_path":"/sec/sgmt/8-k/2026-06-03/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ****Financial","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-070126-index.html","accession_number":"0001104659-26-070126","cik":"0001400118","ticker":"SGMT","issuer_name":"Sagimet Biosciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-070126-index.html","primary_entity_key":"0001400118","primary_entity_name":"Sagimet Biosciences Inc."},"word_count":80,"has_tables":true,"body_markdown":"**Item 9.01****Financial\nStatements and Exhibits.**\n\n** **\n\n**(d) Exhibits**\n\n** **\n\nExhibit\n\nNo.\n \nDocument\n\n[10.1](tm2616747d1_ex10-1.htm)\n \n[Form\nof Performance-Based Restricted Stock Unit Award Agreement.](tm2616747d1_ex10-1.htm)\n\n104\n \nCover Page Interactive\nData File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n** **\n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nas amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \nSagimet Biosciences Inc.\n\n \n \n \n\nDate: June 3, 2026\nBy:\n/s/ David Happel\n\n \n \nDavid Happel\n\n \n \nChief Executive Officer"}